- Home
- PLX vs CRBP Comparison
PLX vs CRBP Comparison
Compare PLX & CRBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLX
- CRBP
- Stock Information
- Founded
- PLX 1993
- CRBP 2009
- Country
- PLX United States
- CRBP United States
- Employees
- PLX N/A
- CRBP N/A
- Industry
- PLX Biotechnology: Biological Products (No Diagnostic Substances)
- CRBP Biotechnology: Pharmaceutical Preparations
- Sector
- PLX Health Care
- CRBP Health Care
- Exchange
- PLX Nasdaq
- CRBP Nasdaq
- Market Cap
- PLX 127.4M
- CRBP 114.8M
- IPO Year
- PLX 1998
- CRBP N/A
- Fundamental
- Price
- PLX $1.91
- CRBP $9.37
- Analyst Decision
- PLX Strong Buy
- CRBP Strong Buy
- Analyst Count
- PLX 1
- CRBP 10
- Target Price
- PLX $15.00
- CRBP $53.22
- AVG Volume (30 Days)
- PLX 705.4K
- CRBP 91.8K
- Earning Date
- PLX 11-13-2025
- CRBP 11-06-2025
- Dividend Yield
- PLX N/A
- CRBP N/A
- EPS Growth
- PLX N/A
- CRBP N/A
- EPS
- PLX 0.08
- CRBP N/A
- Revenue
- PLX $61,948,000.00
- CRBP N/A
- Revenue This Year
- PLX $14.53
- CRBP N/A
- Revenue Next Year
- PLX $75.77
- CRBP $220.04
- P/E Ratio
- PLX $24.60
- CRBP N/A
- Revenue Growth
- PLX 62.79
- CRBP N/A
- 52 Week Low
- PLX $0.99
- CRBP $4.64
- 52 Week High
- PLX $3.10
- CRBP $56.93
- Technical
- Relative Strength Index (RSI)
- PLX 70.20
- CRBP 47.64
- Support Level
- PLX $1.52
- CRBP $9.42
- Resistance Level
- PLX $1.69
- CRBP $9.73
- Average True Range (ATR)
- PLX 0.08
- CRBP 0.49
- MACD
- PLX 0.03
- CRBP -0.09
- Stochastic Oscillator
- PLX 91.67
- CRBP 19.37
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.
About CRBP Corbus Pharmaceuticals Holdings Inc.
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.